Abstract:Introduction Idiopathic inflammatory myopathies (IIMs) encompass a diverse group of diseases characterized by considerable variability in clinical manifestations, antibody profiles, and responsiveness to immunosuppressive therapies. This study aimed to investigate the association between organ involvement and distinct myositis autoantibodies in individuals with IIM in a single-center cohort. Methods Patients with ICD diagnoses M33.1, M33.2, M33.9, or M609 who (1) had been tested with Euroline blot assay for myositis autoantibodies and (2) met the classification criteria of definite/probable polymyositis (PM) or dermatomyositis (DM), anti-synthetase syndrome (ASS), or inclusion body myositis (IBM) were included. Medical journals were retrospectively examined with respect to clinical disease features. Results Seventy patients (median age 58 years; 66% females) were included and represented the following diagnosis: PM ( n = 23), DM ( n = 21), ASS ( n = 23), and IBM ( n = 3). Most of the patients (87%) presented a muscle biopsy indicative of myositis. The presence of autoantibodies was as follows: myositis-specific antibodies, MSA ( n = 53), myositis-associated antibodies, MAA ( n = 33), both MSA + MAA ( n = 24), MSA only ( n = 29), MAA only ( n = 9), no MSA, or MAA ( n = 8). Anti-Jo-1 was the most common MSA (19%), whereas the most common MAA was anti-Ro/SSA52 (31%). We observed a significant association between antibody patterns and lung disease. In our cohort, 47% of the patients in the whole study group, 86% of patients with anti-SSA52, and 100% with anti-Jo-1 had pulmonary involvement. Patients with both MSA and MAA had a higher incidence of lung disease and decreased CO-diffusion capacity. This was especially prominent in anti-Ro/SSA52-positive patients. Interestingly, none of the patients suffered from lung disease if only antibodies against Mi-2α, Mi-2β, NXP2, HMGCR, and TIF1γ were present or no MSA/MAA were detected. Discussion: The simultaneous presence of both MAA and MSA indicates an increased risk of lung involvement in patients with inflammatory myopathies. The presence of any MAA, and especially anti-Ro/SSA52, is associated with more severe pulmonary disease. Our data suggest that MAA antibodies might be relevant markers for early detection and treatment of lung involvement in IIM.

Myositis‐associated autoantibodies in juvenile myositis are associated with refractory disease and mortality

Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients

Myositis-associated antibodies predict the severity of lung involvement in adult patients with inflammatory myositis − a cohort study of 70 adult patients with myositis in a single center

Prevalence and Clinical Implications of Autoantibodies in Juvenile Dermatomyositis: A Single-Center Experience From India

Myositis-specific Autoantibodies in Adults with Idiopathic Inflammatory Myopathy: Correlations with Diagnosis and Disease Activity

Comparison of Clinical Features and Prognostic Factors of Polymyositis/Dermatomyositis Associated Interstitial Lung Disease According to Autoantibodies: Anti-Aminoacyl tRNA Synthetase Antibodies Versus Anti-Melanoma Differentiation-Associated Gene 5 Antibody.

Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan

The presence of myositis specific and myositis associated antibodies does not alter prognosis in IPF

The Clinical Significance of Myositis-Specific Antibodies in Polymyositis/dermatomyositis Associated Interstitial Lung Diseases

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

Recent research on myositis-specific autoantibodies in juvenile dermatomyositis

Myositis autoantibodies and clinical phenotypes

[Clinical Value of Myositis Antibodies in Patients with Connective Tissue Disease-Associated Interstitial Lung Diseases].

Clinical Significance of Myositis-Specific and Myositis-Associated Antibody Profiles in Dermatomyositis

An update on autoantibodies in the idiopathic inflammatory myopathies

Comment On: 'Anti-Ro52 Autoantibodies Are Associated with Interstitial Lung Disease and More Severe Disease in Patients with Juvenile Myositis' by Sabbagh Et Al

Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease

Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort

Anti‐MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 disease

Narrative Review of Autoantibodies in Idiopathic Inflammatory Myopathies